| BUSINESS STRATEGY |
Another track toward this goal is niche generics, which are, generic versions of small-volume brand-name products with annual sales ranging from $5 million to $25 million.
Because Co is a relatively small company, being first to file to get market exclusivity is not a top priority, Spiegler says. Instead, Co looks for products that are of little interest to big generic companies. Teva Pharmaceuticals, the largest generic company in the world, "is not going to spend time and money targeting a brand-name product with only $25 million in sales," he explains. "It could use the same resources for a product with $100 million in sales."
|